Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors

Mohammad H. Abu-Arja, Diana S. Osorio, Alvaro Lassaletta, Richard T. Graham, Scott L. Coven, Joseph R. Stanek, Eric Bouffet, Jonathan L. Finlay, Mohamed S. Abdelbaki

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

We aimed toidentify prognostic factors that may help better understand the behavior of relapsed central nervous system nongerminomatous germ cell tumors. We identified nine studies, including 101 patients; 33 patients (33%) were alive 12 months post-initial relapse. Sixty percent of patients with serum/cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) level ≤25 ng/mL at initial diagnosis were survivors compared with 28% among patients with serum/CSF AFP level >25 ng/mL (P = 0.01). Seventy-one percent of patients who achieved complete response/continued complete response (CR/CCR) by the end of therapy at relapse were survivors compared with 7% among patients who had less than CR/CCR (P < 0.0001). Forty-eight percent of patients who received marrow-ablative chemotherapy followed by autologous hematopoietic cell rescue (HDCx/AuHCR) following relapse were survivors compared with 12% among patients who did not receive HDCx/AuHCR (P = 0.0001). Local relapse site, gross total surgical resection, and radiotherapy at relapse were not associated with improved outcomes.

Original languageEnglish
Article numbere29365
JournalPediatric Blood and Cancer
Volume69
Issue number1
DOIs
StatePublished - Jan 2022

Keywords

  • Central nervous system
  • germ cell tumors
  • nongerminomatous germ cell tumors
  • recurrence
  • relapse

Fingerprint

Dive into the research topics of 'Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors'. Together they form a unique fingerprint.

Cite this